Search results for "Thrombolysi"

showing 10 items of 120 documents

Trans-catheter thrombolysis and endovascular relining to treat acute stent graft limb occlusion: technical report

2012

abdominal aortic aneurysm endovascular repair limb occlusion thrombolysisSettore MED/22 - Chirurgia Vascolare
researchProduct

Abciximab Facilitates the Rate and Extent of Thrombolysis

1999

Background —The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a potent and safe addition to reduced-dose thrombolytic regimens for ST-segment elevation MI. Methods and Results —Patients (n=888) with ST-elevation MI presenting <12 hours from onset of symptoms were treated with aspirin and randomized initially to either 100 mg of accelerated-dose alteplase (control) or abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 μg · kg −1 · min −1 ) alone or in combination with reduced doses of alteplase (20 to 65 mg) or streptokinase (500 000 U to 1.5 MU). Control patients recei…

business.industrymedicine.medical_treatmentStreptokinaseReteplaseThrombolysismedicine.diseaseBolus (medicine)Physiology (medical)AnesthesiamedicineAbciximabPlatelet aggregation inhibitorMyocardial infarctionCardiology and Cardiovascular MedicinebusinessTIMImedicine.drugCirculation
researchProduct

Effects of Administration of Glycoprotein IIb/IIIa Receptor Antagonists in Patients with Failed Thrombolysis

2001

Aim To evaluate the effectiveness of glycoprotein (GP) IIb/IIIa receptor antagonists in patients with acute myocardial infarction (AMI) who have undergone unsuccessful thrombolysis.

chemistry.chemical_classificationmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGeneral MedicineThrombolysisTirofibanmedicine.diseaseGastroenterologyPharmacotherapychemistryInternal medicinemedicineAbciximabEptifibatidePharmacology (medical)cardiovascular diseasesMyocardial infarctionGlycoproteinbusinessReceptormedicine.drugClinical Drug Investigation
researchProduct

Gender-related differences in men and women with ST-segment elevation myocardial infarction and incomplete infarct-related artery flow restoration: a…

2018

Introduction: Little is known about gender-related differences in ST-segment elevation myocardial infarction (STEMI) and incomplete infarct-related artery (IRA) reperfusion after primary percutaneous coronary intervention (pPCI). Aim: To evaluate gender-related differences in clinical characteristics and prognosis in patients with STEMI and incomplete IRA reperfusion after pPCI. Material and methods: From 42,752 STEMI patients hospitalized between 2009 and 2011 in Poland we analyzed a group of 984 (36%) females and 1,746 (64%) males with less than Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow following pPCI. Results: Women were older than men (72.0 ±11.3 vs. 64.0 ±11.7 years; p …

gender-related differencesmedicine.medical_specialtymedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arteryMedicineST segmentcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrythrombolysis in myocardial infarctionlcsh:RPercutaneous coronary interventionSudden cardiac arrestThrombolysismedicine.diseaseprimary percutaneous coronary interventionHeart failureRight coronary arteryCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessTIMIST-segment myocardial infarctionAdvances in Interventional Cardiology
researchProduct

Mechanical rotational thrombectomy with Rotarex system augmented with drug-eluting balloon angioplasty vs. stenting for the treatment of acute thromb…

2018

Introduction Mechanical thrombectomy is an alternative to local thrombolysis for the treatment of severe ischaemia in the femoropopliteal segment, but stent implantation is usually required after this procedure. The use of drug-eluting balloons (DEBs) may overcome long-term problems associated with stents, but it remains unclear how often such a treatment is technically feasible and efficient. Aim This post hoc single-centre study was aimed at assessment of the feasibility, safety and efficacy of mechanical thrombectomy followed by application of DEBs. Material and methods Fifty-one patients, aged 69.1 ±11.6 years, were managed for acute thrombotic or chronic critical ischaemia in the femor…

medicine.medical_specialtyAcute limb ischaemiaUrologymedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyBalloon03 medical and health sciencesmechanical thrombectomy0302 clinical medicineacute limb ischaemiaAngioplastymedicine030212 general & internal medicinecritical ischaemiaOriginal Paperbusiness.industryMortality ratelcsh:RGastroenterologyObstetrics and GynecologyStentThrombolysismedicine.diseaseSurgeryDissectiondrug-eluting balloonAmputationSurgerystentbusiness
researchProduct

In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism.

2020

AbstractAimsCatheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recent guidelines acknowledge this treatment option for patients with overt or imminent haemodynamic decompensation, particularly when systemic thrombolysis is contraindicated. We investigated patients with PE who underwent catheter-directed thrombolysis (CDT) in the German nationwide inpatient cohort.Methods and resultsData from hospitalizations with PE (International Classification of Disease code I26) between 2005 and 2016 were collected by the Federal Office of Statistics in Germany. Patients with PE who underwent CDT (OPS 8-838.60 or OPS code 8-83b.j) were compared with patients receiving…

medicine.medical_specialtyCathetersTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineLower risk03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineMedicineHumansDecompensationThrombolytic Therapy030212 general & internal medicineProspective StudiesRetrospective Studiesbusiness.industryMortality rateGeneral MedicineOdds ratioThrombolysismedicine.diseaseHospitalsPulmonary embolismTreatment OutcomeCohortCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFibrinolytic agentEuropean heart journal. Acute cardiovascular care
researchProduct

Flegmasia cerulea dolens en paciente con carcinoma testicular

2006

Describimos un caso de flegmasia cerulea dolens secundaria a una trombosis venosa profunda por compresión de la vena cava inferior, en un varón de 31 años con un tumor germinal. Necesitó un tratamiento urgente con agentes fibrinolíticos, heparina intravenosa y quimioterapia. Con el tratamiento obtuvo una respuesta completa tumoral y una completa revascularización de la vena cava y vena femoral derecha.

medicine.medical_specialtyChemotherapybusiness.industryUrologymedicine.medical_treatmentFemoral veinFlegmasia cerulea dolensThrombolysismedicine.diseaseRevascularizationInferior vena cavaSurgeryVenous thrombosisTumor germinalmedicine.veinTrombosis venosacardiovascular systemMedicinecardiovascular diseasesRadiologybusinessGerm cell tumourTrombolisisPhlegmasia cerulea dolensActas Urológicas Españolas
researchProduct

Stroke Care Within the COVID-19 Pandemic—Increasing Awareness of Transient and Mild Stroke Symptoms Needed

2020

Background: The COVID-19 pandemic might affect health care resources and alter patient admission to hospital in case of stroke or transient ischemic attack (TIA). We aim to determine whether the COVID-19 pandemic is affecting utilization of recanalization procedures and numbers of patients with stroke and TIA admitted to a primary care stroke center.Methods: In this retrospective observational study, we compared patients admitted from January 2019 until February 2020 with patients admitted during the COVID-19 pandemic (March/April 2020) in Germany. We included patients with stroke (hemorrhagic or ischemic) or TIA as classified by International Statistical Classification of Diseases and Rela…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.medical_treatmentMild strokecerebral ischemialcsh:RC346-42903 medical and health sciencesmechanical thrombectomy0302 clinical medicineInternal medicinePandemicmedicineInternational Statistical Classification of Diseases and Related Health Problemscerebral infarct030212 general & internal medicinecardiovascular diseasesStrokelcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryCOVID-19Retrospective cohort studyThrombolysismedicine.diseaseMechanical thrombectomyNeurologytransient ischemic attackNeurology (clinical)business030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Pulmonary embolism hotline 2012. Recent and expected trials.

2012

SummaryManagement of acute pulmonary embolism (PE) has advanced considerably in the past year, and progress is expected to continue in 2013. To help determine the optimal management strategy for normotensive patients with intermediate-risk PE, the Pulmonary Embolism Thrombolysis (PEITHO) study completed enrolment of 1006 patients with evidence of right ventricular dysfunction (by echocardiography or computed tomography) plus a positive troponin test. Patients have been randomised to thrombolytic treatment with tenecteplase versus placebo, and the effects on clinical end points (death or haemodynamic collapse) assessed at 7 and 30 days. The results are expected in spring 2013; long-term foll…

medicine.medical_specialtyDeep veinmedicine.medical_treatmentTenecteplase030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolytic AgentsEdoxabanmedicineHumans030212 general & internal medicineRivaroxabanClinical Trials as TopicEvidence-Based Medicinebusiness.industryHematologyThrombolysismedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureTreatment OutcomechemistryAnesthesiaApixabanbusinessPulmonary Embolismmedicine.drugForecastingHamostaseologie
researchProduct

Effects of Two Different ACE Inhibitors, Captopril and Delapril, in the Early Phases of Acute Anterior Myocardial Infarction

1999

Objective: This study was aimed at investigating the effects of captopril or delapril before and just after thrombolysis in acute anterior myocardial infarction (AMI). Patients and Methods: Study participants consisted of 89 patients, hospitalised within 4 hours of the onset of symptoms. Patients were randomly divided into two groups: the first group (45 patients, pretreatment group) received captopril 6.25mg or delapril 7.5mg orally about 15 minutes before intravenous administration of recombinant tissue plasminogen activator (rt-PA) 100mg; the second group (44 patients, late-treatment group) received captopril or delapril about 4 to 6 hours after thrombolytic treatment. Captopril/delapril…

medicine.medical_specialtyEjection fractionbiologybusiness.industrymedicine.medical_treatmentDelaprilCaptoprilGeneral MedicineThrombolysismedicine.diseaseBlood pressureHeart failureInternal medicinemedicinebiology.proteinCardiologyPharmacology (medical)Creatine kinasecardiovascular diseasesMyocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct